Current Report Filing (8-k)
12 10월 2018 - 12:19AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 11, 2018 (September 17, 2018)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
100
South Saunders Rd, Suite 150, Lake Forest
|
|
IL
60045
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code
+1(847)574 6288
One
International Place, Suite 1400, Boston, MA 02110
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement
On
September 17, 2018, Luckwel Pharmaceuticals Inc. (the “Company”) entered into an online office lease agreement with
Regus Management Group, LLC to lease an office space located at 100 S. Saunders Road, Suite 150, Lake Forest, IL 60045 for $284.69
per month. The Company will now be headquartered at this address and its telephone number has been changed to (847)574 6288. The
lease expires on March 31, 2019.
This
description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Agreement,
a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.
Item 9.01
Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL PHARMACEUTICALS INC.
|
|
|
Date:
October 11, 2018
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Luckwel Pharmaceuticals Inc (GM) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Luckwel Pharmaceuticals Inc. News Articles